Niall M.B. Martin

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.7K citations

Life Sciences, Genetics, Molecular Biology +16

Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM

Ian Hickson, Yan Zhao, Caroline J. Richardson et al. · Cancer Research · 2004 · 1.2K citations

Life Sciences, Molecular Biology, Oncology +16

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Sven Rottenberg, Janneke E. Jaspers, Ariena Kersbergen et al. · Proceedings of the National Academy of Sciences · 2008 · 949 citations · Full text

Medicine, Oncology, Pharmacology +16

4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2<i>H</i>-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1

Keith Menear, Claire Adcock, Robert Boulter et al. · Journal of Medicinal Chemistry · 2008 · 586 citations · Full text

Medicine, Oncology, Pharmacology +16

Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i> -Mutated Mouse Mammary Tumors

Janneke E. Jaspers, Ariena Kersbergen, Ute Boon et al. · Cancer Discovery · 2012 · 515 citations · Full text

Medicine, Oncology, Pharmacology +17